Behavioral: Questionnaires ( DrugBank: - )


2 diseases
IDDisease name (Link within this page)Number of trials
28Systemic amyloidosis1
49Systemic lupus erythematosus1

28. Systemic amyloidosis


Clinical trials : 261 Drugs : 276 - (DrugBank : 81) / Drug target genes : 68 - Drug target pathways : 178
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01807286
(ClinicalTrials.gov)
January 20146/3/2013Pomalidomide With Melphalan and Dexamethasone for Untreated Systemic AL AmyloidosisA Phase I/II Clinical Trial of Pomalidomide With Melphalan and Dexamethasone in Patients With Newly Diagnosed Untreated Systemic AL Amyloidosis: Trial Stopped During Phase IMyelomaDrug: Pomalidomide;Drug: Melphalan;Drug: Dexamethasone;Behavioral: QuestionnairesM.D. Anderson Cancer CenterCelgeneTerminated18 YearsN/ABoth3Phase 1United States

49. Systemic lupus erythematosus


Clinical trials : 946 Drugs : 722 - (DrugBank : 186) / Drug target genes : 117 - Drug target pathways : 199
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04276701
(ClinicalTrials.gov)
March 10, 202112/2/2020Immune Mediators and Metabolites to Stratify Systemic Lupus Erythematosus Patients at High Risk of Cardio Vascular DiseasesImmune Mediators and Metabolites to Stratify Systemic Lupus Erythematosus Patients at High Risk of Cardio Vascular DiseasesSystemic Lupus ErythematosusBiological: blood sample;Other: Ultrasonography assessment;Behavioral: questionnairesUniversity Hospital, BordeauxFoundation for Research in Rheumatology (FOREUM)Recruiting18 YearsN/AAll500N/AFrance;Germany;Spain